Profitelligence Profitelligence · Filing Ledger Open MRNA research →

Form 8-K · Current Report · Filed 2025-11-13

Moderna Approves One-Time Stock Option Exchange Program

On November 12, 2025, Moderna, Inc. held a Special Meeting of Shareholders where the stockholders approved a one-time stock option exchange program for non-Executive Committee employees by a vote of 231,049,158 For, 6,167,159 Against, and 250,409 Abstain. Additionally, they approved the adjournment of the meeting if necessary by a vote of 223,991,059 For, 13,198,386 Against, and 277,281 Abstain. No broker non-votes were recorded.

Filer
Moderna Inc. MRNA · NASDAQ
Filed
Accession
0001628280-25-052055
CIK
0001682852
Signal
Medium impactHealthcare

Items reported

Item 5.07

Submission of Matters to a Vote of Security Holders

Equity Plan Approved Say-on-Pay Approved

Market reaction

Close before filing

$26.71

Next session

-7.3%

Since filing

+105.2%

Latest close

$54.82

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from MRNA reporting the same item, with the next session's move:

About Moderna Inc.

Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.

Exchange NASDAQ Industry Biotechnology Company website ↗

Never miss another MRNA filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts